Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- 74% of Healthcare Organizations Rate Their Patient Data Quality as Mixed or Poor, New Clinical Architecture Report FindsCARMEL, Ind., August 24, 2026--New report reveals a growing healthcare data trust gap, with poor-quality patient data creating challenges for interoperability and care.
- QurAlis to Participate in Upcoming Investor Conferences in SeptemberCAMBRIDGE, Mass., August 24, 2026--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will participate at the following investor conferences in September. Management will also participate in one-on-one investor meetings.
- PCB TechnologiesPCB Technologies Announces Winning of a USD 65 Million Tender for the Supply of Medical PCB Assembly Products in 2027-2028PCB Technologies (TASE: PCBT), a global leader in advanced electronic and PCB manufacturing solutions, is pleased to announce that on August 23, 2026, it was awarded a tender for the supply of electronic packaging products in 2027-2028...
- Sustainable Cookware Industry Analysis and Forecast 2026-2035 Featuring Profiles of Groupe SEB, Meyer Corporation, ZWILLING J.A. Henckels, Scanpan, Tramontina and MoreHealth, Safety and Sustainability Trends Drive Demand for Durable, Chemical-Free Cookware as Material Innovation and Direct-to-Consumer Sales Expand
- GSKJemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancerCompanies: GSKIf approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients.
- TakedaORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1OSAKA, Japan & CAMBRIDGE, Mass., August 24, 2026--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine or
- TME Pharma provides update on its activitiesTME Pharma enters final evaluation phase with two potential partners for licensing lead asset NOX-A12 to support Phase 2 glioblastoma development
- Pulnovo MedicalPulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart DiseasePulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clinical trial, conducted under a U.S. Food and Drug...
- CPKCRecord $4.95 million raised for heart health in Alberta as Miyu Yamashita wins CPKC Women's OpenThe 2026 CPKC Women's Open raised a record $4.95 million to support heart healthcare in Alberta, while on the golf course, Miyu Yamashita concluded a historic performance on Sunday to capture the 2026 CPKC Women's Open and her fourth LPGA Tour...
- Antengene Corporation LimitedAntengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&DAntengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- AnBogen TherapeuticsAnbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication ExpansionAnbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate...
- InterSystems Asia READY 2026 to Showcase AI-Ready HealthcareBANGKOK, August 24, 2026--InterSystems, a creative data technology provider managing over one billion healthcare records globally, will bring healthcare leaders from across Asia to Bangkok for InterSystems Asia READY 2026, where the focus will be on how trusted data, interoperability, and practical artificial intelligence (AI) can accelerate smarter healthcare delivery and strengthen Thailand's position as a regional medical hub.